Clinical trials: End-Stage Kidney Disease
Kidney Failure, Chronic, Healthy Volunteers
A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis
The purpose of this study is to assess the effect of severe renal impairment (RI) and end-stage renal disease (ESRD) with intermittent hemodialysis (IHD) on the pharmacokinetics and safety of BMS-986278.
- Conditions
- Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
- Trial name
- NCT06723535
- Testing
- BMS-986278
- Where
- 4 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
End Stage Renal Disease
Randomised Study of High-flux Haemodialysis and Haemodiafiltration
The most common forms of renal replacement therapy currently in use are high flux haemodialysis (HF-HD) and haemodiafiltration (HDF).
- Trial name
- NCT01862679
- Testing
- High-flux haemodialysis, Haemodiafiltration
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- NHS Greater Glasgow and Clyde
Type 2 Diabetes, Diabetic Nephropathy
Pioglitazone and Losartan Provides Additional Renoprotection
Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II…
- Trial name
- NCT00364988
- Testing
- pioglitazone+losartan, losartan
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
End Stage Kidney Disease, Delayed Graft Function
Better Evidence for Selecting Transplant Fluids
End-stage kidney disease (ESKD) is a significant, expensive health problem. Kidney transplantation improves survival, quality of life, and is much cheaper than dialysis treatment for ESKD.
- Conditions
- End Stage Kidney Disease, Delayed Graft Function, Kidney Transplant; Complications
- Trial name
- BEST-Fluids (NCT03829488)
- Testing
- Plasma-Lyte 148 (approx. pH 7.4) IV Infusion, 0.9% SODIUM CHLORIDE 9g/L injection BP
- Where
- 18 sites in Australia, New Zealand
- Volunteers
- 808 people
- Sponsor
- The University of Queensland
End Stage Renal Disease
Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2
The investigators' overarching goal is to improve long-term outcomes for end stage renal disease (ESRD) patients. In this study we focus specifically on patients receiving peritoneal dialysis (PD).
- Trial name
- NCT02212327
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Chronic Kidney Disease, End Stage Kidney Disease
Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
The mortality rate of treated patients with end stage renal disease(ESRD)is 22 deaths patient-years at risk in 2006. Incident patients with ESRD are most vulnerable within the first 90 days of dialysis, with an annualized…
- Conditions
- Chronic Kidney Disease, End Stage Kidney Disease, Cardiovascular Disease
- Trial name
- NCT00792454
- Testing
- exercise training
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- MaineHealth
Kidney Failure, Chronic
Clinical Study to Assess the Performance of the Dialyzer With Endexo™
Endexo™ is an additive that is blended into the fiber solution during manufacturing of the hemodialyzer hollow fibers. The intended purpose of the additive is to increase blood compatibility in the finished dialyzer, which is…
- Trial name
- NCT03536663
- Testing
- Optiflux and Dialyzer with Endexo
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fresenius Medical Care North America
Chronic Renal Disease
Once-a-day Immunosuppression(CISECON_a_day)
The objective of this study is to assess the efficacy and safety and Immunosuppressant Therapy Barrier Scale (ITBS) of once daily immunosuppressant maintenance therapy in patients who had kidney transplantations earlier.
- Trial name
- CISECON (NCT01964014)
- Testing
- advagrf
- Where
- 7 sites in South Korea
- Volunteers
- 160 people
- Sponsor
- Ajou University School of Medicine
Dialysis, Chronic Kidney Disease (Stages 3b-5)
Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study
Objectives: This pilot study aims to evaluate the safety and efficacy of left atrial appendage occlusion (LAAO) in dialysis patients and atrial fibrillation (AF) to establish a novel stroke prevention strategy and determine an…
- Conditions
- Dialysis, Chronic Kidney Disease (Stages 3b-5), Atrial Fibrillation, End Stage Kidney Failure
- Trial name
- LAAO-DAF (NCT07257614)
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
End Stage Renal Disease, End Stage Liver Disease
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
This study utilizes a web-based application to help patients on the organ transplant waitlist communicate patient's need for a living donor via social media and provide interested potential donors the opportunity to engage with…
- Trial name
- NCT03803423
- Testing
- The Donor App
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Heart Failure, Copd
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health.
- Conditions
- Heart Failure, Copd, Liver Failure, Diabetes Mellitus
- Trial name
- NCT04351880
- Testing
- Medically Tailored Meals
- Where
- 2 sites in United States
- Volunteers
- 650 people
- Sponsor
- Kaiser Permanente
Chronic Kidney Disease Stage 5, Mineral Metabolism Disorder
Acute Changes in the Mineral Metabolism After a High Phosphorous Containing Meal in Dialysis Patients
The purpose of the study is to investigate whether a high phosphorous containing meal causes acute changes in p-phosphate levels in patients with dialysis-dependent kidney failure.
- Trial name
- NCT03868371
- Testing
- High phosphorous containing meal, Low phosphorous containing meal
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Herlev Hospital
Chronic Kidney Disease Requiring Hemodialysis, End Stage Renal Disease (ESRD)
Early Feasibility Study of the Velocity™ Percutaneous Arterio-Venous Fistula System for Creating Hemodialysis Vascular Access
The Velocity Percutaneous Arterio-Venous System is a minimally invasive method of creating hemodialysis vascular access. The study aims to understand clinical efficacy and initial clinical safety data of the device.
- Trial name
- VENOS-2 (NCT06712251)
- Testing
- Velocity pAVF System
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Venova Medical
Intradialytic Hypotension, End-Stage Renal Disease Requiring Haemodialysis
Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension
This multicenter, prospective observational study aims to evaluate the predictive value of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) for hypotension during maintenance hemodialysis.
- Conditions
- Intradialytic Hypotension, End-Stage Renal Disease Requiring Haemodialysis, Uremia; Chronic, Hemodialysis
- Trial name
- CUPID (NCT07033260)
- Testing
- Non-invasive Monitoring
- Where
- China
- Volunteers
- 183 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Primary Hyperoxaluria Type 1, End Stage Renal Disease
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
- Trial name
- PHYOX7 (NCT04580420)
- Testing
- DCR-PHXC
- Where
- 18 sites in United States, France and 8 more
- Volunteers
- 28 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
End-Stage Renal Disease, Renal Disease, End-Stage
Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Our study addresses the following research question: What is the role of obesity in modulating inflammation and innate immune function, as well as the overall responsiveness of innate immune cells (such as macrophages…
- Conditions
- End-Stage Renal Disease, Renal Disease, End-Stage, Renal Failure, End-Stage, Obesity
- Trial name
- NCT01691196
- Where
- United States
- Sponsor
- University of Illinois Chicago
End Stage Renal Failure on Dialysis
Hemodialysis Blood Flow and Urea Clearance
The study purpose is to determine whether two different hemodialysis blood flow rates each meet national dialysis standards for urea clearance. Urea is used as the primary marker of dialysis adequacy.
- Trial name
- NCT02484118
- Testing
- Hemodialysis blood flow
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- University of British Columbia
Kidney Diseases, End-Stage Kidney Disease
Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag)
Many patients on hemodialysis have low levels of magnesium. Magnesium is needed to keep the heart, kidneys, and other organs working properly.
- Conditions
- Kidney Diseases, End-Stage Kidney Disease, Hemodialysis
- Trial name
- NCT04079582
- Testing
- Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L)., Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).
- Where
- Canada
- Volunteers
- 25,000 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Dyslipidemia
Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers
To analyze efficacy of fluvastatin on patients with chronic renal disease by analyzing certain inflammatory markers. In addition, tolerability and safety will also be evaluated in a Spanish population.
- Trial name
- NCT00171262
- Testing
- Fluvastatin
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Novartis
Healthy
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with varying degrees of renal impairment
- Trial name
- NCT00637403
- Testing
- Megestrol acetate concentrated suspension 125 mg/mL
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.